News >

O'Regan Highlights CDK4/6 Agents, Other Developments in ER+ Breast Cancer

Brandon Scalea
Published: Tuesday, Nov 27, 2018

Dr. Ruth O'Regan

Ruth O'Regan, MD
Endocrine therapy has long been a standard approach for patients with estrogen receptor (ER)-positive breast cancer, but there is an unmet need for the patients who develop resistance to this treatment.

, O’Regan discussed the current landscape of HR-positive breast cancer and the unanswered questions that still need to be addressed.

OncLive: What are the updates in HR-positive breast cancer treatment? 

O’Regan: The most dramatic thing that has happened in ER-positive breast cancer is that most patients do not need chemotherapy. More than 70% of patients with ER-positive, node-negative breast cancer do not need chemotherapy. From the TAILORx study led by Dr Joseph Sparano, what we know is that women under the age of 50 benefit from chemotherapy if they have recurrence scores over 16. Therefore, the question is, “How can we manage those patients?” If we are going to give them chemotherapy, there are several trials suggesting that you can use a less aggressive regimen.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication